OMER - OMEROS CORP
Region: US
Website: omeros.com
Employees: 210
IPO year: 2009
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing
Omeros Corporation discovers, develops, and commercializes small-molecule and protein therapeutics. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that has completed pivotal studies for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA) and atypical hemolytic uremic syndrome (aHUS) The company was incorporated in 1994 and headquartered in Seattle, Washington.
Omeros Corp (OMER) Q4 2024 Earnings Call Highlights: Navigating Financial Challenges with ...
Despite a significant net loss, Omeros Corp (OMER) focuses on strategic partnerships and a promising pipeline to bolster its financial position and future growth.
Read moreOmeros: Q4 Earnings Snapshot
SEATTLE (AP) — Omeros Corporation OMER on Monday reported a loss of $31.4 million in its fourth quarter. The Seattle-based company said it had a loss of 54 cents per share. Losses, adjusted to account for discontinued operations, came to 63 cents per share.
Read more